NR3C1表达与前列腺癌生化复发的相关性研究

doi:10.3969/j.issn.1000-8535.2020.04.005

广州医药 ›› 2020, Vol. 51 ›› Issue (4): 22-27.DOI: 10.3969/j.issn.1000-8535.2020.04.005

NR3C1表达与前列腺癌生化复发的相关性研究

岑昕贝¹, 凌济忠¹, 万跃平², 万颂², 华伟², 江敏耀², 习明²

1 广州市花都区花山镇卫生院外科(广州 510880)
2 南方医科大学花都区人民医院泌尿外科(广州 510800)

收稿日期:2019-11-05 出版日期:2020-07-20 发布日期:2021-11-28
通讯作者: 习明,E-mail: 32069366@qq.com
基金资助:
广东省科技计划项目(2014A020212471);广州市科技计划项目(201607010398);花都区科技计划项目(HD15CXY005,15-HDWS-068)

Correlation analysis between the expression level of NR3C1 and biochemical recurrence of prostate cancer

CEN Xinbei¹, LING Jizhong¹, WAN Yueping², WAN Song², HUA Wei², JIANG Minyao², XI Ming²

1 Department of Surgery,Huashan Town Health Center,Guangzhou 510880,China
2 Department of Urology,Huadu District People's Hospital,Southern Medical University,Guangzhou 510800,China

Received:2019-11-05 Online:2020-07-20 Published:2021-11-28

摘要/Abstract

摘要： 目的研究NR3C1(核受体亚科3,C组,成员1)又称糖皮质激素受体(GR)表达量对前列腺癌恶性程度的影响及其与前列腺癌生化复发的相关性。方法通过组织芯片免疫组化染色检测的方法检验NR3C1在不同恶性程度前列腺癌组织的表达情况,结合Taylor数据库分析NR3C1表达水平与前列腺癌临床病理特征关系,再采用Kaplan-Meier法分析NR3C1对前列腺癌生化复发生存率的影响,最后用Cox回归分析临床病理特征与生化复发的相关性。结果组织芯片免疫组化结果显示NR3C1在Gleason评分低的前列腺癌组织中表达高于Gleason评分高的前列腺癌组织(P=0.028)。结合Taylor公用数据库分析,NR3C1在前列腺癌组织中的表达低于癌旁组织(P＜0.001),NR3C1在Gleason评分低的前列腺癌组织中表达高于Gleason评分高的前列腺癌组织(P=0.005),NR3C1低表达与PSA复发(P=0.028)和转移(P=0.003)相关。Kaplan-Meier结果提示:NR3C1高表达组患者术后的生化复发生存率更高(P=0.043),总体生存率没有明显区别(P=0.872)。单因素分析结果显示:NR3C1(P=0.002),病理分期(P＜0.001),Gleason评分(P＜0.001),是否转移(P=0.012)是前列腺癌生化复发的影响因素。多因素分析结果显示:高Gleason 评分(P=0.017)和转移(P<0.001)均为生化复发危险因素。结论 NR3C1影响前列腺癌的发病进程,检验NR3C1的表达情况,能预测前列腺癌患者生化复发的概率,可协助判断前列腺癌预后。

关键词: NR3C1, 前列腺癌, 生化复发, 预后

Abstract: Objective We study the role of NR3C1 (nuclear receptor subfamily 3,group C,member 1) in PCa progression,and the correlation between its expression level and the biochemical recurrence of PCa. Methods Immunohistochemistry was used to detect the expression of NR3C1 in PCa tissues of different degrees of malignancy. The associations of NR3C1 expression and clinical pathological features were analyzed using the Taylor dataset. Kaplan-Meier was used to detect the relationship between NR3C1 expression and biochemical recurrence survival rate in PCa. Cox-regressive analysis was used to detect the relationship between clinical pathological features and biochemical recurrence. Results Immunohistochemistry analysis showed the expression of NR3C1 was higher in which its Gleason Score was lower(P=0.028). Base on the Taylor dataset,the expression of NR3C1 was higher in the adjacent benign tissues than that in PCa(P＜0.001). The expression of NR3C1 was higher in which its Gleason Score was lower(P=0.005). Furthermore,low NR3C1 expression was associated with PSA failure(P=0.028) and Metastasis(P=0.003). Kaplan-Meier showed the biochemical recurrence-free time of PCa patients in low NR3C1 expression groups reduced(P=0.043). The overall survival time of PCa patients was not correlated to NR3C1 expression levels(P=0.872). Single factor analysis showed the biochemical recurrence is associated with NR3C1 expression(P=0.002),pathological stage(P＜0.001),Gleason score(P＜0.001), Metastasis status(P=0.012). Multivariate analysis by Cox regression further identified the high Gleason Score(P=0.017) and Metastasis status (P<0.001)were hazards of the biochemical recurrence. Conclusion Our study showed that the expression of NR3C1 critically connected with the process of PCa,which indicated that we can predict the probability of the biochemical recurrence and determine the prognosis of prostate cancer by detecting the expression of NR3C1 in PCa patients.

Key words: NR3C1, Prostate cancer, Biochemical recurrence, Prognosis

岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.

CEN Xinbei, LING Jizhong, WAN Yueping, WAN Song, HUA Wei, JIANG Minyao, XI Ming. Correlation analysis between the expression level of NR3C1 and biochemical recurrence of prostate cancer[J]. Guangzhou Medical Journal, 2020, 51(4): 22-27.

参考文献

[1] SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,2019[J]. CA Cancer J Clin,2019,69(1):7-34.
[2] HAMDY F C,DONOVAN J L,LANE J A,et al. 10-year outcomes after monitoring,surgery,or radiotherapy for localized prostate cancer[J]. N Engl J Med,2016,375(15): 1415-1424.
[3] GROSSMAN D C,CURRY S J,OWENS D K,et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement[J]. Ann Intern Med,2012(157): 120-134.
[4] ALANAZI I O,ALSHEHRI Z S,EBRAHIMIE E,et al. Non-coding and coding genomic variants distinguish prostate cancer,castration-resistant prostate cancer,familial prostate cancer,and metastatic castration-resistant prostate cancer from each other[J]. Mol Carcinog,2019,58(6):862-874.
[5] LIU Y,WANG J,YANG T,et al. Overexpression levels of cripto-1 predict poor prognosis in patients with prostate cancer following radical prostatectomy. [J]. Oncol Lett,2019,18(3):2584-2591.
[6] POLO A,MARCHESE S,de PETRO G,et al. Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder,prostate,kidney cancers[J]. Sci Rep,2018,8(1):10395.
[7] 李雯,林江涛,孙力超,等. p38丝裂原活化蛋白激酶抑制剂SB203580对糖皮质激素敏感性的影响机制[J]. 中华医学杂志,2012,92(36): 2570-2573.
[8] 赵海波,吴永定,曾彦茹,等. NEK2与前列腺癌预后的相关研究[J]. 广州医药,2017,48(2): 1-5.
[9] CHEN W Q,ZHENG R S,BAADE P D,et al. Cancer statistics in China[J]. CA Cancer J Clin,2016,66(2): 115-32.
[10] CHANNING J P,EISENBERGER M A. Progress in the systemic management of advanced prostate cancer: the hormone-sensitive paradigm[J]. J Clin Oncol,2019,9(4): [Epub ahead of pring].
[11] JI C,WANG W,LU Q,et al. A new technique in fresh prostate cancer tissue biobanking based on MRI-transrectal ultrasound fusion biopsy[J]. Urol,2019,12(134): 186-191.
[12] ISIKBAY M,OTTO K,KREGEL S,et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer[J]. Horm Cancer,2014,5(2):72-89.
[13] CHEN H T,YU H J,WANG J Q,et al. Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci[J]. Prostate, 2015,75(12):1264-1276.
[14] HIROKI I,SATOSHI I,HIROSHI M. The role of glucocorticoid receptor signaling in bladder cancer progression[J]. Cancers (Basel),2018,10(12):484.
[15] LOENARDI D B,ANSELMINO N,BRANDANI J N,et al. Heme oxygenase 1 impairs glucocorticoid receptor activity in prostate cancer[J]. Int J Mol Sci,2019,20(5):1006.

NR3C1表达与前列腺癌生化复发的相关性研究

Correlation analysis between the expression level of NR3C1 and biochemical recurrence of prostate cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	肖驰, 周雪, 徐丹, 杨美英, 费晶, 巩平. SNCG在卵巢癌中的表达及其临床意义[J]. 广州医药, 2021, 52(5): 1-7.
[2]	张林洋, 朱玲玲, 朱国华. 中医药治疗前列腺癌研究进展[J]. 广州医药, 2021, 52(5): 135-138.
[3]	古嘉基, 连泳欣, 丘福满. m6A甲基化基因风险评估模型在卵巢癌预后的临床意义[J]. 广州医药, 2021, 52(3): 1-8.
[4]	谢艳林, 董燕, 柳建华. 经胸超声心动图在Stanford A型主动脉夹层的诊断及预后评估中的价值[J]. 广州医药, 2021, 52(3): 36-40.
[5]	罗水妹, 黄颂平, 许白兰, 沈冰寒. 肺癌并发肺栓塞的危险因素及预后分析[J]. 广州医药, 2021, 52(2): 40-45.